104 related articles for article (PubMed ID: 9263017)
1. Diversity of epitopes recognized by cytotoxic T lymphocytes that are specific for rejection antigen peptide pRL1a presented on BALB/c leukemia RL Male 1.
Yokoi T; Uenaka A; Ono T; Onizuka S; Inoue H; Nakayama E
Int Immunol; 1997 Aug; 9(8):1195-201. PubMed ID: 9263017
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of autoreactive CD4 T cells in generation of cytotoxic T lymphocytes on in vitro stimulation with H-2 class I-binding tumor antigen peptide.
Honda S; Wada H; Uenaka A; Nakayama E
Int Immunol; 1998 Aug; 10(8):1167-74. PubMed ID: 9723703
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia.
Manki A; Ono T; Uenaka A; Seino Y; Nakayama E
Cancer Res; 1998 May; 58(9):1960-4. PubMed ID: 9581839
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
[TBL] [Abstract][Full Text] [Related]
5. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H-2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815.
Van den Eynde B; Mazarguil H; Lethé B; Laval F; Gairin JE
Eur J Immunol; 1994 Nov; 24(11):2740-5. PubMed ID: 7525302
[TBL] [Abstract][Full Text] [Related]
6. Analysis of CD8 T-cell response by IFNgamma ELISPOT and H-2L(d)/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c x C57BL/6) F(1) mice.
Takada I; Noguchi Y; Kenjo A; Wada H; Uenaka A; Fujita T; Inoue H; Nakayama E
Cancer Sci; 2004 Mar; 95(3):254-9. PubMed ID: 15016326
[TBL] [Abstract][Full Text] [Related]
7. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
Uenaka A; Nakayama E
Cancer Sci; 2003 Nov; 94(11):931-6. PubMed ID: 14611667
[TBL] [Abstract][Full Text] [Related]
8. Production of murine leukemia RLmale1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b.
Ono T; Uenaka A; Nakayama E
Jpn J Cancer Res; 1996 Nov; 87(11):1165-70. PubMed ID: 9045946
[TBL] [Abstract][Full Text] [Related]
9. Identification of a CD4 T-cell epitope in tumor rejection antigen RLakt on BALB/c radiation-leukemia RL male 1.
Kaya S; Uenaka A; Sato S; Ono T; Aji T; Nakayama E
Cancer Sci; 2008 Jul; 99(7):1441-7. PubMed ID: 18452555
[TBL] [Abstract][Full Text] [Related]
10. Generation of cytotoxic T-lymphocytes to a self-peptide/class I complex: a model for peptide-mediated tumor rejection.
Tjoa BA; Kranz DM
Cancer Res; 1994 Jan; 54(1):204-8. PubMed ID: 7505197
[TBL] [Abstract][Full Text] [Related]
11. Expression of multiple unique rejection antigens on murine leukemia BALB/c RLmale symbol1 and the role of dominant Akt antigen for tumor escape.
Matsuo M; Wada H; Honda S; Tawara I; Uenaka A; Kanematsu T; Nakayama E
J Immunol; 1999 Jun; 162(11):6420-5. PubMed ID: 10352255
[TBL] [Abstract][Full Text] [Related]
12. Effect of point mutations in the native simian virus 40 tumor antigen, and in synthetic peptides corresponding to the H-2Db-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones.
Deckhut AM; Tevethia SS
J Immunol; 1992 May; 148(10):3012-20. PubMed ID: 1374447
[TBL] [Abstract][Full Text] [Related]
13. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
Uenaka A; Ono T; Akisawa T; Wada H; Yasuda T; Nakayama E
J Exp Med; 1994 Nov; 180(5):1599-607. PubMed ID: 7964448
[TBL] [Abstract][Full Text] [Related]
14. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells.
Ota S; Ono T; Morita A; Uenaka A; Harada M; Nakayama E
Cancer Res; 2002 Mar; 62(5):1471-6. PubMed ID: 11888922
[TBL] [Abstract][Full Text] [Related]
15. An immunodominant epitope present in multiple class I MHC molecules and recognized by cytotoxic T lymphocytes.
Mann DW; McLaughlin-Taylor E; Wallace RB; Forman J
J Exp Med; 1988 Jul; 168(1):307-24. PubMed ID: 2456370
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
Kuhröber A; Schirmbeck R; Reimann J
Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
[TBL] [Abstract][Full Text] [Related]
17. Class I-restricted cytotoxic T cell recognition of split peptide ligands.
Gillanders WE; Hanson HL; Rubocki RJ; Hansen TH; Connolly JM
Int Immunol; 1997 Jan; 9(1):81-9. PubMed ID: 9043950
[TBL] [Abstract][Full Text] [Related]
18. Immunization with synthetic peptides containing a defined malaria epitope induces a highly diverse cytotoxic T lymphocyte response. Evidence that two peptide residues are buried in the MHC molecule.
Romero P; Eberl G; Casanova JL; Cordey AS; Widmann C; Luescher IF; Corradin G; Maryanski JL
J Immunol; 1992 Mar; 148(6):1871-8. PubMed ID: 1541825
[TBL] [Abstract][Full Text] [Related]
19. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
20. Mapping of epitopes recognized by alloreactive cytotoxic T lymphocytes using inhibition by MHC peptides.
Heath WR; Vitiello A; Sherman LA
J Immunol; 1989 Sep; 143(5):1441-6. PubMed ID: 2474598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
